| Literature DB >> 27492477 |
Peter Abbink1, Rafael A Larocca1, Rafael A De La Barrera2, Christine A Bricault1, Edward T Moseley1, Michael Boyd1, Marinela Kirilova1, Zhenfeng Li1, David Ng'ang'a1, Ovini Nanayakkara1, Ramya Nityanandam1, Noe B Mercado1, Erica N Borducchi1, Arshi Agarwal1, Amanda L Brinkman1, Crystal Cabral1, Abishek Chandrashekar1, Patricia B Giglio1, David Jetton1, Jessica Jimenez1, Benjamin C Lee1, Shanell Mojta1, Katherine Molloy1, Mayuri Shetty1, George H Neubauer1, Kathryn E Stephenson1, Jean Pierre S Peron3, Paolo M de A Zanotto3, Johnathan Misamore4, Brad Finneyfrock4, Mark G Lewis4, Galit Alter5, Kayvon Modjarrad6, Richard G Jarman2, Kenneth H Eckels2, Nelson L Michael2, Stephen J Thomas2, Dan H Barouch7.
Abstract
Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Here we demonstrate that three different vaccine platforms protect against ZIKV challenge in rhesus monkeys. A purified inactivated virus vaccine induced ZIKV-specific neutralizing antibodies and completely protected monkeys against ZIKV strains from both Brazil and Puerto Rico. Purified immunoglobulin from vaccinated monkeys also conferred passive protection in adoptive transfer studies. A plasmid DNA vaccine and a single-shot recombinant rhesus adenovirus serotype 52 vector vaccine, both expressing ZIKV premembrane and envelope, also elicited neutralizing antibodies and completely protected monkeys against ZIKV challenge. These data support the rapid clinical development of ZIKV vaccines for humans.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27492477 PMCID： PMC5237380 DOI： 10.1126/science.aah6157
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728